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Background
An important methodological focus in comparative effectiveness 
research (CER) is the advancement of pragmatic clinical trials 
(PCTs),1 which overlap conceptually with practical trials,2 large 
simple trials,3 and effectiveness trials. The approach strives to 
generate results that are relevant to patients and clinicians by 
comparing interventions in participants and settings representative 
of usual care. Pragmatic trials and trial infrastructure have been 
supported through initiatives at NIH,4,5 the Centers for Medicare 
& Medicaid Services,6 the Agency for Healthcare Research and 
Quality (AHRQ),7 the Patient-Centered Outcomes Research 
Institute (PCORI),8 Practice-Based Research Networks (PBRNs),9 
and community-based participatory research initiatives across 
the Federal government.10
A challenge for these initiatives has been the lack of sustained 
research infrastructure to support them. For this reason, the NIH 
Clinical and Translational Science Awards (CTSA) Consortium 
launched an effort in 2012 to advance such an infrastructure. 
The proposed PCT infrastructure (PCTi) would attempt to align 
CTSA and other research institutions, their partners, and the 
NIH National Center for Advancing Translational Sciences on a 
common goal of developing and deploying an infrastructure to 
support high-priority PCTs. Such an infrastructure might also 
serve as a learning ground and shared resource for investigators 
and communities interested in developing PCTs.
Approach
We undertook a three-stage process to build infrastructure that 
could support PCTs within the CTSA Consortium: developing a 
researcher network; prioritizing proposed trials; and implementing 
learning exercises that would culminate in a 1-day workshop.
Developing the network
We held a 1-day meeting to launch a national network of 
thought leaders on infrastructure for PCTs. A 32-member 
planning committee (Table 1) drew representatives from 17 
CTSAs and other organizations with expertise in stakeholder 
and community engagement (Supplement: Community 
and Stakeholder Engagement Experience of Coauthors), 
quantitative and qualitative research methods, informatics, 
CER, dissemination and implementation research, and a range 
of clinical and health systems topics relevant to developing a 
strategic plan for development of PCT research infrastructure. 
The planning committee began by reviewing existing definitions 
of PCTs.11,12 These definitions place PCTs on a continuum with 
explanatory trials but with a focus on comparisons of clinical, 
community and health systems interventions. This led to the 
following definitions:
•	 	 A pragmatic clinical trial is a prospective comparison of a 
community-, clinical-, or system-level intervention and a 
relevant comparator in participants who are similar to those 
affected by the condition(s) under study and in settings 
that are similar to those in which the condition is typically 
treated.
•	 	 A pragmatic clinical trial infrastructure includes the resources, 
systems, and processes needed to prioritize, conduct, and use 
the results of PCTs.
Three goals that emerged were to: (1) generate a set of 
recommendations for building a PCTi; (2) catalyze PCT research 
projects within CTSA-affiliated research consortia; and (3) 
evaluate the performance of this initiative through an iterative 
learning network approach. Thereby, the intent was to learn by 
doing; to learn how to build infrastructure from the experience 
of launching actual trials.
Prioritizing proposed trials
To accomplish these goals, the planning committee solicited 
PCT proposals to serve as illustrative “use cases” for a learning 
network of CTSA members and partners. A solicitation was 
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issued to members of the CTSA community in July 2012; 19 
proposals were submitted by investigators and reviewed by a 
subgroup of the planning committee by early September. The 
proposals were reviewed on eight primary and five secondary 
criteria (Figure 1). Primary review criteria were considered 
“must-have” features of each use case. Secondary criteria were 
considered “desired” features. Five illustrative use cases were 
selected (Table 2), representing a range of interventions in 
inpatient and outpatient settings, varied study designs, and both 
pediatric and adult populations. Summaries of the use cases are 
presented below and more detailed descriptions can be found 
on the CTSA Consortium Web site.13
The nicotine replacement for hospitalized smokers (NICHOLS) 
study
The objectives of the proposed research are to compare the 
effectiveness and cost-effectiveness of counseling plus nicotine 
replacement therapy (NRT) versus counseling alone in hospitalized 
smokers. The investigators propose a cluster-randomized design, 
using hospitals (N = 50) as the unit of randomization. The 
investigators hypothesize that counseling plus NRT will result 
in higher abstinence rates, better health status, and lower rates of 
acute care utilization post discharge than will counseling alone 
among hospitalized smokers. Counseling is to be delivered by 
an experienced, guideline-based telephone counseling service 
Name Affiliation
Sergio Aguilar-Gaxiola University of California, Davis, California
Syed Ahmed Medical College of Wisconsin, Milwaukee, Wisconsin
Arthur Blank Albert Einstein College of Medicine, New York, New York
Kathleen Brady Medical University of South Carolina, Charleston, South Carolina
Tim Carey The University of North Carolina, Chapel Hill, North Carolina
Thomas Concannon Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts
Linda Cottler University of Florida, Gainesville, Florida
Rowena Dolor Duke University, Durham, North Carolina
Milton Eder University of Chicago, Chicago, Illinois
Alecia Fair Clinical and Translational Science Awards Consortium Coordinating Center, Vanderbilt University, 
Nashville, Tennessee
Carol Ferrans University of Illinois, Chicago, Illinois
Rosemarie Filart National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland
Dan Ford Johns Hopkins University, Baltimore, Maryland
Mark Helfand Oregon Health & Science University, Portland, Oregon
William Hersh Oregon Health & Science University, Portland, Oregon
Larry Kessler University of Washington, Seattle, Washington
Jerry Krishnan University of Illinois, Chicago, Illinois
Colleen Lawrence Clinical and Translational Science Awards Consortium Coordinating Center, Vanderbilt University, 
Nashville, Tennessee
Paul Meissner Albert Einstein College of Medicine, New York, New York
Lloyd Michener Duke University, Durham, North Carolina
Peter Neumann Tufts University, Boston, Massachusetts
Iris Obrams National Center for Advancing Translational Science, NIH, Bethesda, Maryland
Wilson Pace University of Colorado, Denver, Colorado
Harold Pincus Columbia University, New York, New York
Al Richmond The University of North Carolina, Chapel Hill, North Carolina
Gary Rosenthal University of Iowa, Iowa City, Iowa
Joel Saltz Emory University, Atlanta, Georgia
Andrea Sawczuk National Center for Advancing Translational Science, NIH, Bethesda, Maryland
Harry Selker Tufts University, Boston, Massachusetts
Jodi Segal Johns Hopkins University, Baltimore, Maryland
Jonathan Tobin The Rockefeller University, New York, New York
Sean Tunis Center for Medical Technology Policy, Baltimore, Maryland
Table 1. PCTi workshop planning committee.
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at the point of care in hospitals and in the outpatient setting. 
Medications will be provided during the hospitalization and 
then prescribed for use after hospital discharge for 12 weeks; 
follow-up would continue for an additional 12 weeks. To mimic 
clinical practice, medications after discharge will not be funded 
by the study and will be administered by clinicians, not research 
staff. Biochemically verified 7-day abstinence from smoking at 
24 weeks will be the primary endpoint, assessed by intention-to-
treat. Secondary outcomes will include patient-reported health 
status, acute care utilization over 24 weeks, total and mean costs, 
and incremental cost-effectiveness ratios from the health system, 
insurer, and societal perspectives. Subgroup analyses will examine 
effects by race, gender, age, reason for hospital admission, and 
income.
Figure 1. Proposal review criteria.
Principal investiga-
tor & affiliation
Study design Population Intervention vs. 
comparator
Outcomes Setting
Nicotine replacement for hospitalized smokers (NICHOLS) study
Jerry Krishnan, 
University of Illinois 
Chicago


















utilization, and days 
absent from school.
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RCT Adult Usual care vs. usual 
care + decoloniza-
tion in the home






Clustered RCT Adult Decision support 
with and without 
nurse telephone 
support
Total dose of narcot-
ics prescribed
Outpatient
Multimodal intervention to reduce the risk for major adverse cardiovascular events
Karl Hammermeis-
ter, University of 
Colorado Denver





RCT = randomized clinical trial; NRT = nicotine replacement therapy; PBRN= practice-based research network; PharmD = doctor of pharmacy.
Table 2. Use case investigators and proposed pragmatic clinical trials.
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The case of translating and implementing evidence-based 
childhood asthma interventions in federally qualified health 
centers (FQHCs)
The proposed study is designed to: (1) evaluate the decisions 
that FQHC leaders make to deploy and sustain evidence-based 
childhood asthma interventions; (2) evaluate the effectiveness of 
interventions once integrated into FQHC routine practice; and (3) 
communicate and disseminate findings to other FQHCs across the 
United States. The investigators plan to select three “intervention” 
and three matched (on organizational characteristics and 
pediatric populations) “comparison” FQHCs that jointly represent 
a variation in capacity, experience with asthma, resources in the 
community, and local policy. The comparison interventions will 
consist of: (1) asthma counseling tailored to the environmental 
triggers to which a child is sensitive, an intervention used by the 
National Cooperative Inner City Asthma Study; (2) home-based 
environmental remediation, an intervention used by the Inner 
City Asthma Study; and (3) a “hybrid” counseling and remediation 
intervention. All three were previously found to be efficacious in 
reducing symptom days, inappropriate utilization of services, and 
days absent from school. However, previous studies did not engage 
primary care practices as a matter of protocol, thereby leaving out 
an important element in understanding how the interventions 
may be implemented in real-world clinical settings.
Community-acquired methicillin-resistant Staphylococcus 
aureus bacteria (CA-MRSA) treatment and transmission 
prevention
The purpose of this proposed research is to compare clinical and 
community-based interventions among patients presenting with 
skin and soft tissue infections (SSTIs) and diagnosed with CA-
MRSA who are seen in primary care settings. The interventions 
to be compared are: (1) standard CDC guideline-directed care, 
including incision, drainage, and oral antibiotics (usual care), and 
(2) usual care with decolonization interventions conducted in the 
home setting, including hygiene education, twice daily intranasal 
mupirocin and daily chlorhexidine body washes (usual plus 
experimental care). Patients will be enrolled through outreach 
to PBRNs, their community health centers, primary care practices, 
and primary care clinicians. Follow-up at 3, 6, and 12 months after 
baseline will measure short- and long-term clinical response, 
and identify primary care, emergency department, inpatient, 
laboratory, and pharmacy utilization for SSTIs.
Chronic pain self-management
The proposed research is designed to compare promotion of 
lifestyle guidelines that have been shown to reduce pain, including 
breathing relaxation and distraction, as well as to improve patient–
provider communication, patient social support, and medication 
adherence. The investigators propose a 2-year, cluster-randomized 
controlled trial with interventions at both the provider and patient 
levels. Primary care providers will be randomized to have access 
to a decision support interface or usual care without the decision 
support interface. Within each participating provider’s primary 
care panel, patients with chronic pain will be randomized to 
receive either a nurse telephone intervention focused on self-
management, or usual primary care. The patient will be the 
unit of analysis, and the primary outcome will be the total dose 
of narcotic medications prescribed over the study period. The 
investigators hypothesize that narcotic medication prescriptions 
will be lower for patients whose providers have access to the 
decision support interface and who receive the nurse telephone 
intervention.
Multimodal intervention to reduce the risk for major 
adverse cardiovascular events: enhancing blood pressure and 
cholesterol guideline concordance
The purpose of the proposed research is to improve prescription 
guideline concordance in patients at risk for major adverse 
cardiovascular events. The Investigator proposes to conduct 
a randomized pragmatic trial of intervention and usual care 
clinics caring for approximately 2,800 nonconcordant patients. 
The intervention is to consist of monthly PharmD-led meetings 
with enrolled patients, presentation of an educational curriculum, 
and evaluation of patient-specific medication issues including side 
effects, adherence, and guideline concordance. At the conclusion 
of each session, the PharmD will either modify prescriptions or 
inform the primary care provider of proposed modifications to 
prescriptions, to achieve guideline concordance. Investigators 
will meet monthly with clinic directors and medical directors to 
evaluate clinic- and study-level concordance data. Outcomes of 
interest include: patient-, care provider-, and practice-level factors 
associated with successful implementation of the intervention; 
sustainability of the intervention; and the incremental costs of 
intervention.
Implementing learning exercises
The planning committee worked for 2 months with principal 
investigators of the five selected proposals and developed “use 
cases” that were presented at a 1-day, in-person learning network 
meeting in November 2012. We paired investigators with a 
member of the planning committee to address 13 questions 
(Figure 2) that explore the infrastructure strengths and needs of 
individual PCTs. Investigators redeveloped their proposals into 
“use cases” that were distributed to individuals who had registered 
online for the 1-day learning network meeting. The meeting was 
attended by 97 individuals representing 40 CTSA institutions, 
the NIH, Clinical Research Organizations, community leaders, 
the Institute of Medicine (IOM), and stakeholder organizations. 
The use cases were presented in early sessions.
Most of the meeting was devoted to studying the cases’ 
infrastructure capacities and needs. Participants and investigators 
discussed strategies to develop and sustain the proposed research 
programs, following a semistructured format addressing a range 
of infrastructure domains: (1) dissemination and implementation 
research; (2) informatics and information technology; (3) CER 
methods; (4) community and stakeholder engagement; and (5) 
evaluation of research.
The discussions yielded practical solutions to support the 
launch and conduct of the proposed studies. Each workshop 
participant initially stayed with the discussion surrounding one 
of the five use cases, and later participated in a plenary meeting 
headed by small roundtables of experts representing the five 
infrastructure domains. The individual challenges and solutions 
that applied to one use case were compared and synthesized with 
those of the others. Finally, the recommendations were vetted and 
redrafted in an iterative process over 3 months of discussion with 
our planning committee’s infrastructure experts.
Recommendations
Five recommendations grew out of this process (Table 3): 
develop a sustained PCT learning network, establish standing 
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infrastructure for community and stakeholder engagement, 
ease regulatory challenges, advance two domains in 
information technology, and improve research methods to 
study heterogeneity in PCTs. The recommendations and brief 
discussions are:
Develop a sustained PCT learning network
The role of CTSAs is not to conduct trials, but rather to support 
their conduct by others, by facilitating efficient development and 
implementation. In this role, CTSAs and the Consortium should 
work with the NIH Institutes and Centers, the NIH Collaboratory 
initiative, NIH Common Fund initiatives, AHRQ, and PCORI 
to stimulate and share process learning through the conduct of 
high-priority trials. The CTSA-supported activities could include 
consultation with trial investigators, documentation of trials, and 
development of investigator learning opportunities. This activity 
would require the redirection of resources within CTSAs, could 
leverage other trial infrastructure, and might depend on new 
resources from Federal and other funders.
Establish standing infrastructure to engage with communities 
and stakeholders
Community14 and stakeholder engagement15 are valued 
functions of  individual CTSAs and the Consortium. 
Investigators planning PCTs need community and stakeholder 
(patients, caregivers, providers, funders, employers, policy 
makers, product makers, etc.) input and advice regarding 
issues of study topic and design, acceptable methods for 
participant recruitment and participation, appropriate 
choice of study outcomes, and methods for dissemination of 
results. Assessing research priorities and obtaining feedback 
on research populations and the most important study 
outcomes currently is conducted project by project, often 
taking 6 months or more. Yet, this input is needed in advance 
of research planning, and investigators are often confronted 
by short proposal timelines of 6 to 8 weeks, which makes 
an authentic process of this type very challenging. Because 
engagement of communities and stakeholders is relatively new, 
trialists are still learning how to make this process efficient 
Figure 2. Use case review questions.
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and effective. While some activities may need to engage 
communities and other stakeholder de novo, use of standing 
stakeholder groups could be a more efficient alternative. These 
structures may help to establish a culture of engagement 
among researchers, long-term bidirectional relationships 
between researchers and stakeholders, and timely advising 
on research. The downsides of such an approach may include 
high time and resource costs, increased stakeholder fatigue,16 
inability to include members representing every condition and 
disease group of interest, and a risk of paradoxically creating 
the perception by researchers that standing structures alone 
can provide sufficient support for research proposals and 
projects.
An area to be explored is whether such functions 
could, or should, be shared across several CTSAs, such as 
engaging with condition-focused advocacy organizations 
and stakeholders for prevalent conditions. For example, the 
COPD Outcomes-Based Network for Clinical Effectiveness & 
Research Translation (CONCERT) has developed a national 
stakeholder consortium for collaborative activities to support 
CER in COPD, including patient advocacy groups, professional 
organizations representing providers, research organizations, 
and others.17 Representatives of national stakeholder groups have 
contributed to CONCERT prioritization activities, preparation 
and submission of applications, recruitment into studies, and 
technical assistance to stakeholder groups seeking COPD CER 
experts. The availability of a “standing” stakeholder consortium 
has proved to be efficient for CONCERT investigators and 
stakeholders, and could serve as a paradigm for research in other 
conditions. These experiences are consistent with the recent 
IOM recommendation that CTSAs “build partnerships” with 
communities and other stakeholders to support engagement 
“across the research spectrum.”18
This activity would require resource support and substantial 
coordination from CTSAs, institutional review boards, and 
oversight agencies.
Ease regulatory challenges
Pragmatic trials that involve interventions 
applied with minimal research oversight 
in heterogeneous sites may be faced 
with multiple and expensive approvals 
for review of informed consent policies, 
without appreciable improvement in subject 
safety.19 Some proposed modifications to 
the “Common Rule” for review of informed 
consent seek to address this challenge,20–23 
and research organizations should be 
active in these discussions. Through their 
regulatory and governance processes, 
CTSAs are currently working on efforts to 
develop centralized IRBs or to “deem” an 
IRB for multisite trials. While such activities 
are possible under current human subject 
regulations, they are not yet widespread.24 
In addition, to reduce burdens associated 
with contracting across institutions, CTSAs 
should identify and share policies and tools 
that improve contracting efficiency. These 
activities would require significant new 
coordination and resources.
Develop standard data formats for common conditions and 
implement secure, standards-based, interoperable information 
systems
Researchers need consistent ways of describing populations, 
conditions, interventions, and outcomes in electronic data. They 
also need tools for data generation, capture, and management, 
including infrastructure to catalog interventions and their 
implementation and methods for efficient data collection. A 
robust, standards-based informatics infrastructure has the 
potential to reduce PCT costs and improve PCT quality. While 
a long-term goal for such an infrastructure has been articulated 
by the CTSA Consortium,1 PCORI25 and the IOM,26 a shorter-
term goal should include standardizing on key variables across 
conditions and insuring that such standards are used in electronic 
health record (EHR) platforms. Tools for using operational EHR 
data should be identified, standardized, and made available to all 
CTSA Consortium members and disseminated more broadly. For 
operational clinical data, attention must be paid to the limitations 
of using such data while adhering to emerging best practices 
for their use.27 The Consortium should also provide targeted 
consultations to investigators as research is developed. Such a 
learning environment, if documented and disseminated, would 
benefit multiple members of the consortium, and it could be the 
basis for sharing resource-saving information system innovations 
across institutions. These activities would require substantial 
redirection or new allocation of resources, and/or collaboration 
with ongoing related efforts.
Improve methods to study treatment, site, and patient 
heterogeneity in PCTs
By their nature, pragmatic trials enroll participants and sites 
with relatively open inclusion and fewer exclusion criteria than 
the typical efficacy trial, leading to a heterogeneous sample. 
In addition, some types of PCT allow modifications to the 
intervention protocol, leading to heterogeneity of the intervention. 
Unless addressed in the study design, these issues could result 
Domain Description
1. Learning network •  Partner with NIH ICs, AHRQ, and PCORI to coordi-
nate PCTi infrastructure components and test with 
use cases
• Develop and document PCTs
• Share investigator learning opportunities
2. Community and stakeholder 
engagement
•  Establish a standing structure for routinely engag-
ing communities, practices, and stakeholders in trial 
development, implementation, and dissemination 
activities
3. Regulatory challenges •  Modify IRB process to support joint approvals for 
 effectiveness studies through a central or deemed IRB
•  Develop strategies to streamline multiinstitutional 
contracting process
4. Information technology •  Implement secure, standards-based, interoperable 
information systems across sites/institutions
•  Develop a comprehensive dictionary of data ele-
ments across platforms
5. Research methods •  Focus methods work on study design and analytical 
approaches that help measure and interpret treat-
ment, site, and patient heterogeneity
NIH IC = Institutes and Centers of the National Institutes of Health; AHRQ = Agency for Healthcare Research 
& Quality; PCORI = Patient-Centered Outcomes Research Institute; PCT = pragmatic clinical trial; IRB = Institu-
tional Review Board.
Table 3. Recommendations for infrastructure to support pragmatic clinical trials.
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in significant challenges for interpretation of PCTs. The CTSA 
Consortium should coordinate among its many committees 
and should engage with the PCORI Methods Committee,24 
AHRQ Effective Healthcare Program,28,29 and others to establish 
common standards for the study of treatment, site, and participant 
heterogeneity. These activities would require redirection of 
resources from CTSAs and new allocations from Federal and 
other funders.
Discussion
There is a growing national interest in research that reflects usual 
care and usual care settings. The rationale is that the results of 
research should be relevant to patients and clinicians, and they 
should be useable in everyday practice. Real-world settings 
typically have greater complexity and heterogeneity than 
traditional trial environments. To improve generalizability, these 
trials depend on larger enrollments and more diverse research 
participants. The infrastructure needed to conduct these studies 
will depend on coordinated and material support from funders, 
research institutions, and individual investigators.
We recommend practical infrastructure changes that can be 
deployed to assist investigators, stakeholders, and communities in 
the development and launch of PCTs within 24 months. Although 
these recommendations were developed for CTSAs and the CTSA 
Consortium, they could be adapted by any public or private 
entity with an interest in PCTs and their infrastructure. Some 
proposed changes could be accomplished with existing CTSA 
infrastructure, requiring coordination of existing personnel and 
resources. Other changes, such as an infrastructure for a sustained 
learning network, may require redirection of existing resources 
or new resources. New information technology innovation will 
require sustained attention and resources. New methods for 
interpreting treatment, site, and patient heterogeneity will also 
require redirected or new resources.
We launched this effort in the CTSA Consortium on 
the assumption that efficient infrastructure changes could 
be developed, evaluated, and validated through case-based 
learning, and we focused our attention on immediate needs for 
the next 2 years. However, we envision a national infrastructure 
that can support and sustain PCTs well into the future. The 
return on this investment of attention, coordination, and 
resources should be to the benefit of the healthcare system 
and the public’s health.
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